Canfeza SEZGİN, Ulus Ali ŞANLI, Rüçhan USLU, Erdem GÖKER

Arsenic trioxide has additive cytototix effects on MCF-7 breast cancer cell line with taxanes

Breast cancer is the most prevalent cancer in women and an important cause of both morbidity and mortality. Although long-term disease-free survival is offered to women with early stage disease by current treatment modality, some, 30-40% of patients will have metastatic disease. Treatment of patients with metastatic disease is a great challenge for oncologists. Therefore, new drugs and therapeutic options for women with metastatic breast cancer are urgently required. Arsenical compounds have cytotoxic effects on several cancer cell lines including promyelocytic leukemia, esophageal carcinoma, megakaryocytic leukemia, and malignant lymphocytic cell lines. In addition, recent studies showed that arsenic trioxide (As2O3) can induce a clinical remission in patients with acute promyelocytic leukemia. In this study, we evaluated the cytotoxic effects of arsenic trioxide (As2O3) alone and combined with Taxane compounds (paclitaxel and docetaxel) on human breast carcinoma cell line MCF-7. It is clearly demonstrated that As2O3 has a significant cytotoxic effect on breast carcinoma cells. IC50 for As2O3 was 5 x 10-6 M after 72 h. Apoptosis of carcinoma cells was responsible for the cytotoxicity of As2O3. The additive effects of taxane compounds with As2O3 were shown. These in vitro results may suggest that As2O3 is a potential new cytotoxic agent for the treatment of breast cancer.

PDF

___

1. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 50: 7, 2000. 2. Greenberg P, Hortobagyi G, Smith T, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205,1996. 3. Perez EA. Current management of metastatic breast cancer. Semin Oncol 26: 1-10, 1999. 4. Waxman S, Anderson KC. History of the Development of Arsenic Derivatives in Cancer Therapy. The Oncologist 6: 3-10,2001. 5. Gallagher RE. Arsenic: new life for an old potion. N Engl J Med 339: 1389-1391, 1998. 6. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide in the treatment of APL. Clinical efficacy and pharmacokinetics. Blood 89: 3354-3360, 1997. 7. Lee TC, Ho IC. Differential cytotoxic effects of arsenic on human and animal cells. Environ Health Perspect 102: 101-105,1994.. 8. Chen GQ, Zhu J, Shi XG, et al. In vitro studies on cellular and molecular mech¬ anisms of arsenic trioxide (As203) in the treatment of APL: As203 induces NB4 cell apoptosis with downregulation of bcl-2 expression and modulation of PML-RARa/PML protein. Blood 88: 1052-1061, 1996. 9. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 48: 353-74, 1997. 10. Von Hoff DD.The taxoids: same roots, different drugs. Semin Oncol 24: 3-13,1997. 11. Long HJ. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin Proc 69: 341-5, 1994. 12. Caplow M, Shanks J, Ruhlen R. How taxol modulates microtubule disassembly. J Biol Chem 23: 399-402, 1994. 13. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997. 14. Abrams JS, Vena DA, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol 13: 2056- 2065, 1995. 15. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14: 1858-1867, 1996. 16. Esteva JF, Valero V, Pusztaı L, et al.Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond. The Oncologist 6: 133-146, 2001. 17. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol 24: 1-18, 1997. 18. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 13: 2643-2655, 1995. 19. Warburton S, James R. Haemocytometer cell counts and viability studies. Cell and tissue culture laboratory procedures (Eds. A. Doyle, J.B. Grifits and D.G. Newell), Chichester, John Wiley, 1994,pp: 411-415. 20. Aragene Y, Kulms D, Metze D, et al.Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/Apo-1)independently of its ligand CD95L. J Cell Biol 140: 171-182, 1998. 21. Li YM, Broome JD. Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59: 776-780, 1999. 22. Uslu R, Sanli UA, Sezgin C, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6: 4957-4964, 2000. 23. Zheng J, Deng YP, Lin C et al. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 82:286-292, 1999. 24. Yang CH, Wang TY, Chen YC. Cytotoxicity of arsenic trioxide in cancer cell lines [abstract 1552]. Proc AACR 39:227, 1998. 25. Shen ZY, Tan L), Cai WJ et al. Arsenic; trioxide induces apoptosis of' oesophageal carcinoma in vitro. Int j Mol Med 4: 33-37, 1999.